Header Logo

Connection

JONATHAN LEI to Breast Neoplasms

Back to Details
This is a "connection" page, showing publications JONATHAN LEI has written about Breast Neoplasms.
JONATHAN LEI
Connection Strength
2.003
Breast Neoplasms
  1. The Breast Cancer Proteome and Precision Oncology. Cold Spring Harb Perspect Med. 2023 10 03; 13(10).
    View in: PubMed
    Score: 0.376
  2. Endocrine therapy resistance: new insights. Breast. 2019 Nov; 48 Suppl 1:S26-S30.
    View in: PubMed
    Score: 0.287
  3. Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer. Cell Rep. 2018 08 07; 24(6):1434-1444.e7.
    View in: PubMed
    Score: 0.263
  4. PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer. Mol Cancer Ther. 2024 Oct 01; 23(10):1494-1510.
    View in: PubMed
    Score: 0.101
  5. Kinome Reprogramming Is a Targetable Vulnerability in ESR1 Fusion-Driven Breast Cancer. Cancer Res. 2023 10 02; 83(19):3237-3251.
    View in: PubMed
    Score: 0.094
  6. Proteogenomic Approaches for the Identification of NF1/Neurofibromin-depleted Estrogen Receptor-positive Breast Cancers for Targeted Treatment. Cancer Res Commun. 2023 07; 3(7):1366-1377.
    View in: PubMed
    Score: 0.093
  7. Molecular portraits of cell cycle checkpoint kinases in cancer evolution, progression, and treatment responsiveness. Sci Adv. 2023 06 30; 9(26):eadf2860.
    View in: PubMed
    Score: 0.092
  8. Elevated NRAS expression during DCIS is a potential driver for progression to basal-like properties and local invasiveness. Breast Cancer Res. 2022 10 18; 24(1):68.
    View in: PubMed
    Score: 0.088
  9. Transcriptional Reprogramming Differentiates Active from Inactive ESR1 Fusions in Endocrine Therapy-Refractory Metastatic Breast Cancer. Cancer Res. 2021 12 15; 81(24):6259-6272.
    View in: PubMed
    Score: 0.082
  10. Proteogenomic Landscape of Breast Cancer Tumorigenesis and Targeted Therapy. Cell. 2020 11 25; 183(5):1436-1456.e31.
    View in: PubMed
    Score: 0.077
  11. Neurofibromin Is an Estrogen Receptor-a Transcriptional Co-repressor in Breast Cancer. Cancer Cell. 2020 03 16; 37(3):387-402.e7.
    View in: PubMed
    Score: 0.073
  12. Copy number alterations associated with clinical features in an underrepresented population with breast cancer. Mol Genet Genomic Med. 2019 07; 7(7):e00750.
    View in: PubMed
    Score: 0.069
  13. DPYSL3 modulates mitosis, migration, and epithelial-to-mesenchymal transition in claudin-low breast cancer. Proc Natl Acad Sci U S A. 2018 12 18; 115(51):E11978-E11987.
    View in: PubMed
    Score: 0.067
  14. Proteomic profiling identifies key coactivators utilized by mutant ERa proteins as potential new therapeutic targets. Oncogene. 2018 08; 37(33):4581-4598.
    View in: PubMed
    Score: 0.065
  15. Loss of MutL Disrupts CHK2-Dependent Cell-Cycle Control through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer. Cancer Discov. 2017 10; 7(10):1168-1183.
    View in: PubMed
    Score: 0.061
  16. Proteogenomics connects somatic mutations to signalling in breast cancer. Nature. 2016 06 02; 534(7605):55-62.
    View in: PubMed
    Score: 0.057
  17. Mammary Ductal Environment Is Necessary for Faithful Maintenance of Estrogen Signaling in ER? Breast Cancer. Cancer Cell. 2016 Mar 14; 29(3):249-250.
    View in: PubMed
    Score: 0.056
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.